Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23170500 | 0.89 | MAOA (0.33) | SLC6A9TRPA1MAOBDPP4 | |
| SCHEMBL23161278 | 0.85 | SLC6A9 (0.34) | SLC6A9ROCK2TRPA1RIPK1GRIN2B | |
| SCHEMBL23161259 | 0.85 | TRPA1 (0.36) | SLC6A9TRPA1MAOBGRIN2B | |
| SCHEMBL23170489 | 0.83 | SLC6A9 (0.40) | SLC6A9GRIN2B | |
| SCHEMBL23162432 | 0.83 | FFAR1 (0.40) | MAOB | |
| SCHEMBL23161285 | 0.83 | L3MBTL1 (0.44) | SLC6A9ROCK2MAOBL3MBTL1RIPK1 | |
| SCHEMBL23170246 | 0.83 | DPP4 (0.36) | SLC6A9DPP4 | |
| SCHEMBL23170622 | 0.81 | DPP4 (0.35) | SLC6A9RIPK1GRIN2BDPP4 | |
| SCHEMBL23161314 | 0.81 | RIPK1 (0.38) | SLC6A9ROCK2L3MBTL1RIPK1DPP4 | |
| SCHEMBL23170530 | 0.79 | GRM5 (0.39) | MAOBGRIN2BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | SLC6A9 4764/4885ROCK2 640/4885TRPA1 3767/4885 |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | SLC6A9 4764/4885ROCK2 640/4885TRPA1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.